| Document Date: 2014-05-21 12:27:22
Open Document File Size: 574,53 KBShare Result on Facebook
City Swiftwater / Oxford / / Company Superior Relative Efficacy Achieved (FIM12) Laboratory / Sanofi Pasteur Inc. / MPH / / Country United States / Scotland / / Event FDA Phase / / IndustryTerm vaccination site / / MedicalCondition Bell’s palsy / Pneumonia / severe allergic reaction / Discharge diagnosis Discharges Ischemic heart disease / influenza-like illness / influenza disease / US. a COPD / headache / Guillain-Barré Syndrome / Chronic obstructive pulmonary disease / acute disseminated encephalomyelitis / Cardiac arrhythmias / hypovolemic shock / prior influenza / VI palsy / Study years Influenza / Stroke / Protocol-defined influenza-like illness / Hospitalizations Due to Influenza / anaphylaxis / influenza illness / Clinical illness / erythema / fever / Stevens-Johnson Syndrome / Septicemia / Osteoarthritis / pain / laboratory-confirmed influenza / Injury / Heart failure / Deaths Due to Influenza / heart attack / diarrhea / Infection / Resp Illness / clinically relevant influenza disease / illness / inactivated influenza / influenza / / MedicalTreatment immunization / active immunization / vaccination / / Organization National Center for Health Statistics / FDA / Centers for Disease Control and Prevention / / Person Corey A. Robertson / / Position Governor / Director / Scientific and Medical Affairs / / Product Fluzone vaccine / / URL http /
SocialTag |
Fluzone® High-Dose Vaccine and FIM12 Efficacy Trial Results Corey A. Robertson, MD, MPH Director, Scientific and Medical Affairs, Sanofi Pasteur